CLINICAL TRIALS PROFILE FOR SOLABEGRON
✉ Email this page to a colleague
Clinical Trials for Solabegron
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00343486 ↗ | Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms | Completed | GlaxoSmithKline | Phase 2 | This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder. |
NCT00394186 ↗ | A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS) | Completed | GlaxoSmithKline | Phase 2 | This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients. |
NCT00401479 ↗ | A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers | Completed | GlaxoSmithKline | Phase 1 | This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time. |
NCT00427596 ↗ | A Two-Part Study to Determine: Best Medication Formulation and Food Effect | Completed | GlaxoSmithKline | Phase 1 | This is a two-part study. Part 1 is designed to find the best modified release formulation of GW423753; Part 2 is designed to use the selected formulation(s) from Part 1 to find out if food affects the way the medication is processed by the body. |
NCT00501267 ↗ | A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder | Completed | GlaxoSmithKline | Phase 1 | The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together |
NCT02938507 ↗ | Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects | Completed | Velicept Therapeutics, Inc. | Phase 1 | The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects. |
NCT03475706 ↗ | Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women | Completed | Velicept Therapeutics, Inc. | Phase 2 | This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate release low dose or high dose tablets, compared to matched placebo, administered twice daily for 12 weeks to adult female subjects with overactive bladder symptoms (frequency, urgency, and predominantly urgency incontinence) for at least 6 months. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Solabegron
Condition Name
Clinical Trial Locations for Solabegron
Trials by Country
Clinical Trial Progress for Solabegron
Clinical Trial Phase
Clinical Trial Sponsors for Solabegron
Sponsor Name